Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled trial. 1998

D S Lange, and H M Richards, and J Guarnieri, and J M Humeniuk, and R C Savin, and B A Reyes, and J Hickman, and D M Pariser, and R J Pariser, and E F Sherertz, and R M Grossman, and E M Gisoldi, and M A Klausner
Janssen Pharmaceutica, Titusville, NJ 08560, USA.

BACKGROUND Tinea versicolor is a common superficial fungal infection caused by a lipophilic yeast. This chronically recurring opportunistic infection is especially prevalent in tropical and semitropical regions. The topical short-term application of ketoconazole 2% shampoo may provide effective and safe therapy for tinea versicolor. OBJECTIVE The purpose of this study was to evaluate the efficacy and safety of a single application (1 day) versus three daily applications (3 days) of ketoconazole 2% shampoo versus placebo shampoo in the treatment of mycologically confirmed tinea versicolor. METHODS Three hundred twelve patients were included in the primary analyses for this 31-day study. Global evaluation scores were measured on days 10 and 31 with a 5-point scale (1 = healed to 5 = worsening), and a cellophane tape test was done at baseline and days 3, 10, and 31. Efficacy was assessed by clinical response, defined as both a global evaluation score of 1 (healed) and a negative cellophane tape test on day 31. Signs and symptoms of tinea versicolor (scaling, itching, erythema, hypopigmentation, hyperpigmentation) also were evaluated at baseline, day 10, and day 31 with a 4-point scale (0 = absent to 3 = severe). RESULTS Both regimens of ketoconazole shampoo were significantly (P < .001) more effective than placebo for rate of clinical response, global evaluation scores, and mycologic outcomes (cellophane tape test). The clinical response rates at day 31 were 73%, 69%, and 5% for the 3-day ketoconazole, 1-day ketoconazole, and placebo groups, respectively. The difference in the efficacy of the two ketoconazole treatment regimens was not statistically significant. There were no significant differences between any of the treatment groups in the number of patients who experienced adverse events. No serious adverse events occurred and no patient withdrew from the trial prematurely because of an adverse event. CONCLUSIONS Ketoconazole 2% shampoo, used as a single application or daily for 3 days, is safe and highly effective in the treatment of tinea versicolor.

UI MeSH Term Description Entries
D007654 Ketoconazole Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. Nizoral,R-41400,R41,400,R41400,R 41400
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006203 Hair Preparations Hair grooming, cleansing and modifying products meant for topical application to hair, usually human. They include sprays, bleaches, dyes, conditioners, rinses, shampoos, nutrient lotions, etc. Cosmetics, Hair,Hair Cosmetic,Hair Preparation,Cosmetic, Hair,Hair Cosmetics,Preparation, Hair,Preparations, Hair
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

D S Lange, and H M Richards, and J Guarnieri, and J M Humeniuk, and R C Savin, and B A Reyes, and J Hickman, and D M Pariser, and R J Pariser, and E F Sherertz, and R M Grossman, and E M Gisoldi, and M A Klausner
September 1986, Journal of the American Academy of Dermatology,
D S Lange, and H M Richards, and J Guarnieri, and J M Humeniuk, and R C Savin, and B A Reyes, and J Hickman, and D M Pariser, and R J Pariser, and E F Sherertz, and R M Grossman, and E M Gisoldi, and M A Klausner
May 2007, Mycoses,
D S Lange, and H M Richards, and J Guarnieri, and J M Humeniuk, and R C Savin, and B A Reyes, and J Hickman, and D M Pariser, and R J Pariser, and E F Sherertz, and R M Grossman, and E M Gisoldi, and M A Klausner
December 1993, Journal of the American Academy of Dermatology,
D S Lange, and H M Richards, and J Guarnieri, and J M Humeniuk, and R C Savin, and B A Reyes, and J Hickman, and D M Pariser, and R J Pariser, and E F Sherertz, and R M Grossman, and E M Gisoldi, and M A Klausner
December 2022, Germs,
D S Lange, and H M Richards, and J Guarnieri, and J M Humeniuk, and R C Savin, and B A Reyes, and J Hickman, and D M Pariser, and R J Pariser, and E F Sherertz, and R M Grossman, and E M Gisoldi, and M A Klausner
January 1992, Mycoses,
D S Lange, and H M Richards, and J Guarnieri, and J M Humeniuk, and R C Savin, and B A Reyes, and J Hickman, and D M Pariser, and R J Pariser, and E F Sherertz, and R M Grossman, and E M Gisoldi, and M A Klausner
April 1983, Cutis,
D S Lange, and H M Richards, and J Guarnieri, and J M Humeniuk, and R C Savin, and B A Reyes, and J Hickman, and D M Pariser, and R J Pariser, and E F Sherertz, and R M Grossman, and E M Gisoldi, and M A Klausner
January 2003, Indian journal of dermatology, venereology and leprology,
D S Lange, and H M Richards, and J Guarnieri, and J M Humeniuk, and R C Savin, and B A Reyes, and J Hickman, and D M Pariser, and R J Pariser, and E F Sherertz, and R M Grossman, and E M Gisoldi, and M A Klausner
April 2007, Arthritis and rheumatism,
D S Lange, and H M Richards, and J Guarnieri, and J M Humeniuk, and R C Savin, and B A Reyes, and J Hickman, and D M Pariser, and R J Pariser, and E F Sherertz, and R M Grossman, and E M Gisoldi, and M A Klausner
May 2023, Homeopathy : the journal of the Faculty of Homeopathy,
D S Lange, and H M Richards, and J Guarnieri, and J M Humeniuk, and R C Savin, and B A Reyes, and J Hickman, and D M Pariser, and R J Pariser, and E F Sherertz, and R M Grossman, and E M Gisoldi, and M A Klausner
May 1996, Journal of the American Academy of Dermatology,
Copied contents to your clipboard!